92 results on '"Kontoyiannis, Dimitrios P."'
Search Results
2. Impact of climate change and natural disasters on fungal infections
3. Social determinants of health as drivers of fungal disease
4. Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors
5. Invasive mould infections in patients from floodwater- damaged areas after hurricane Harvey – a closer look at an immunocompromised cancer patient population
6. Protocol for fungal infection following the induction of epithelial cell loss in larval zebrafish
7. COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it?
8. A 77-Year-Old Man with Multiple Myeloma and a Lytic Bone Lesion
9. Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review
10. Resistance to Antifungal Drugs
11. Do Not Forget Daptomycin as a Cause of Eosinophilic Pneumonia!
12. EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion
13. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?
14. Risk factors for the development of invasive aspergillosis after kidney transplantation: Systematic review and meta-analysis
15. Superficial Thrombophlebitis From Intravenous Pentamidine in Hematopoietic Cell Transplantation Recipient
16. First report of kerion (tinea capitis) caused by combined Trichophyton mentagrophytes and Microsporum canis
17. Serum (1,3)-Beta-d-Glucan has suboptimal performance for the diagnosis of Pneumocystis jirovecii pneumonia in cancer patients and correlates poorly with respiratory burden as measured by quantitative PCR
18. Necrotizing soft tissue invasive aspergillosis in a cancer patient treated with immunosupressants due to checkpoint inhibitor-induced hepatitis
19. Infectious disease consultation for candidaemia
20. EGF-Mediated Suppression of Cell Extrusion During Mucosal Damage Attenuates Opportunistic Fungal Invasion
21. Doxycycline as a potential partner of COVID-19 therapies
22. Checkpoint Inhibition and Infectious Diseases: A Good Thing?
23. Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis
24. Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China
25. Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies
26. A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae
27. Drug delivery and tissue engineering to promote wound healing in the immunocompromised host: Current challenges and future directions
28. Advances in the diagnosis and treatment of fungal infections of the CNS
29. Associations of inflammation with symptom burden in patients with acute myeloid leukemia
30. Clinical Course of Preseptal and Orbital Cellulitis in 50 Immunocompromised Patients with Cancer
31. Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis
32. Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000–2016): Uncommon, with improved survival but still deadly often
33. Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management
34. Time-to-reporting of blood culture positivity and central venous catheter-associated Candida glabrata fungemia in cancer patients
35. Fungal empyema thoracis in cancer patients
36. Mucormycoses
37. Developing an Adoptive T-Cell Therapy for Mucormycosis in High-Risk Patients after HSCT
38. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
39. Aspergillus Cell Wall Melanin Blocks LC3-Associated Phagocytosis to Promote Pathogenicity
40. 526. Innovative Dual CAR-T Cells to Target B-Cell Leukemia and Opportunistic Fungal Agents
41. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies
42. Aspergillus osteomyelitis: Epidemiology, clinical manifestations, management, and outcome
43. The diagnostic yield of skin biopsy in patients with leukemia and suspected infection
44. Rational approach to pulmonary infiltrates in leukemia and transplantation
45. Drosophila melanogaster as a model to explore the effects of methicillin-resistant Staphylococcus aureus strain type on virulence and response to linezolid treatment
46. Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-γ
47. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients
48. Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: How firm is the Aspergillus diagnosis?
49. Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: A retrospective multicenter study
50. Invasive fungal infections in patients with cancer in the Intensive Care Unit
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.